Low-dose naltrexone, or LDN, is prescribed off-label by some clinicians for people with Hashimoto’s. Its appeal is easy to understand: thyroid treatment can leave people searching for answers about fatigue, brain fog and aching muscles. But LDN has not been established as a treatment that reverses Hashimoto’s, lowers thyroid antibodies or restores thyroid function.
A direct thyroid study found no reduction in thyroid-hormone dispensing after LDN began. That finding deserves a place beside the positive personal stories. It also needs an accurate explanation: prescription records cannot tell us everything about symptoms.
What is LDN, and why is it discussed for Hashimoto’s?
Naltrexone is an opioid-receptor antagonist. Its labeled uses include alcohol dependence and blocking the effects of opioids. Hashimoto’s is outside those approved indications. “Off-label” describes that difference; it does not establish whether a treatment works for a particular condition. Naltrexone prescribing information.
Interest in LDN comes partly from proposed effects on inflammatory and immune signaling. Those proposals are a reason to investigate it. They are not equivalent to a demonstrated benefit in people with autoimmune thyroid disease.
Hashimoto’s involves an immune attack on the thyroid. It can eventually cause hypothyroidism, when the gland no longer produces enough hormone. Thyroid-hormone replacement addresses that deficiency. LDN is a different medication with a different purpose. American Thyroid Association.
What did the 898-person thyroid study find?
In 2020, researchers used Norwegian prescription records to compare thyroid-hormone dispensing before and after LDN began in 898 people with hypothyroidism. They found no association between starting LDN and reduced dispensing of levothyroxine or T3. Raknes and Småbrekke, BMC Endocrine Disorders.
This was an observational before-and-after study, rather than a randomized trial. It used hypothyroidism reimbursement codes and could not separate Hashimoto’s from other causes. It also lacked thyroid blood-test results, antibody measurements and symptom scores.
The result does not support promising that LDN will reduce thyroid-medication needs. It does not settle whether a particular symptom improves, because the study did not measure that outcome.
Does LDN lower TPO antibodies?
The Norwegian study did not measure TPO or thyroglobulin antibodies. It cannot substantiate claims that LDN lowers them. A useful trial would need to measure antibodies, thyroid function and symptoms, with a suitable comparison group.
There is a second distinction: a change in an antibody result is not automatically a change in how someone feels or how much hormone their thyroid produces. The American Thyroid Association explains that positive thyroid antibodies can occur while thyroid function remains normal. Hashimoto’s thyroiditis overview.
When a treatment is advertised around “lower antibodies,” the next question is what happened to the patient’s symptoms and thyroid function.
Can LDN help fatigue or brain fog?
Fatigue is the outcome many people care about most. Research in other conditions gives some reason for interest, but it needs to be identified by condition.
A 2020 publication described three people with ME/CFS who reported differing benefits with LDN. It was a case series without a comparison group. BMJ Case Reports.
A separate retrospective study of 59 people with long COVID reported improvements in several symptoms, including fatigue. That study also lacked a randomized placebo comparison. Bonilla and colleagues.
Neither study establishes a Hashimoto’s-specific fatigue benefit. Persistent tiredness can also overlap with sleep problems, other illnesses and medication effects. An evaluation should establish what is being treated before a symptom is attributed entirely to thyroid antibodies.
How long does LDN take to work for Hashimoto’s?
There is no well-established Hashimoto’s-specific response timeline from controlled trials. Online accounts of improvement after a particular number of weeks should not become a promised treatment window.
A more useful clinical discussion defines the symptom being assessed and what would count as meaningful improvement. A clearer workday, less pain and a different laboratory result are separate outcomes.
What are the downsides and medication concerns?
Naltrexone can interfere with opioid medicines and can precipitate withdrawal in people with opioid dependence. Its labeling also includes liver-injury warnings. A clinician needs an accurate medication history, including pain medicines, and relevant liver history. These labeled risks should not be dismissed because the prescription is described as “low-dose.” Prescribing information.
Reliable rates of side effects specifically in people using LDN for Hashimoto’s have not been established by the thyroid study. Product selection and medication directions belong with the prescribing clinician.
Is LDN a peptide or a thyroid-hormone replacement?
Neither. Naltrexone is a small-molecule medication. It is often discussed alongside peptide treatments because both appear in conversations about inflammation, but they are not the same drug class.
Likewise, a prescription for LDN does not establish that thyroid-hormone replacement is no longer needed. The available dispensing study did not demonstrate that effect.
What about weight loss and patient reviews?
The thyroid study did not measure weight loss. It cannot support an LDN weight-loss promise for Hashimoto’s. Positive reviews can describe a person’s experience, but do not isolate the effect of LDN from other treatment changes or fluctuations in symptoms. They are useful questions to bring into a consultation, rather than a substitute for a comparison group.
Questions worth bringing to a consultation
- Which symptom are we trying to improve, and what other causes have been assessed?
- What evidence applies to Hashimoto’s specifically?
- Which benefits are proposed, and which have been measured in people?
- How will we distinguish symptom improvement from a change in thyroid function?
- Do my medicines or medical history create an interaction or safety concern?
- What would lead us to reassess the treatment?
Rebody’s LDN care page describes its consultation and capsule options. For people being evaluated for thyroid-hormone replacement, thyroid care is a separate clinical discussion. Neither product’s availability establishes that it treats the autoimmune cause of Hashimoto’s.
Explore care with Rebody
Explore LDN care with Rebody
See consultation details and 30- or 90-capsule package options. A clinician reviews whether treatment is appropriate for your medical history and goals.